¿Qué servicio? Contacto Solicitud

NCT07757802

Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

← Centro de ensayos clínicos

Campos del registro

Estado general: RECRUITING
Condiciones: HIV
Tipo de estudio: INTERVENTIONAL
Fase: PHASE1
Objetivo principal: PREVENTION
Tipo de intervención: BIOLOGICAL
Intervenciones: DV901-NP, DV902-NP, CH505 TF mRNA-gp160, CH505 w24 mRNA-gp160, ACU-026-001-1
Patrocinador principal: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)

En caché: 2026-10-24 01:14:00

Ver en ClinicalTrials.gov

Resumen breve

This Phase 1 study will evaluate the safety, tolerability, and immune responses of investigational CH505 HIV vaccine regimens in adults in overall good health without HIV. Participants will receive CH505 protein nanoparticle vaccines (DV901-NP) formulated with the investigational adjuvant ACU-026-001-1, followed by either CH505 protein nanoparticle (DV902-NP) or CH505 mRNA vaccine boosters. The study will assess the ability of these regimens to induce HIV-specific immune responses, including B-cell responses associated with the development of broadly neutralizing antibodies. An immunology cohort will also evaluate how the location of booster vaccination affects immune responses.

Contacto

¿Necesita un informe o redacción médica basada en este ensayo?

Solicitar un informe Redacción médica Informe de investigación a medida

Atención al cliente